Total Payments
$5,209
2024 Payments
$616.04
Companies
42
Transactions
226
Medicare Patients
4,468
Medicare Billing
$647,676
Payment Breakdown by Category
Food & Beverage$5,007 (96.1%)
Education$201.98 (3.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,007 | 222 | 96.1% |
| Education | $201.98 | 4 | 3.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Collegium Pharmaceutical, Inc. | $623.20 | 48 | $0 (2024) |
| ABBVIE INC. | $455.42 | 18 | $0 (2024) |
| Medtronic USA, Inc. | $447.04 | 6 | $0 (2019) |
| Medtronic, Inc. | $439.03 | 8 | $0 (2024) |
| Boston Scientific Corporation | $438.38 | 25 | $0 (2022) |
| PFIZER INC. | $369.67 | 27 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $322.72 | 2 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $261.03 | 4 | $0 (2019) |
| Nevro Corp. | $224.08 | 3 | $0 (2019) |
| Amarin Pharma Inc. | $135.24 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $616.04 | 33 | Collegium Pharmaceutical, Inc. ($223.93) |
| 2023 | $729.34 | 45 | Collegium Pharmaceutical, Inc. ($181.59) |
| 2022 | $1,164 | 64 | ABBVIE INC. ($221.03) |
| 2021 | $535.90 | 19 | BOSTON SCIENTIFIC CORPORATION ($212.74) |
| 2020 | $173.03 | 12 | Teva Pharmaceuticals USA, Inc. ($65.71) |
| 2019 | $272.59 | 4 | Medtronic USA, Inc. ($117.28) |
| 2018 | $478.23 | 5 | Kowa Pharmaceuticals America, Inc. ($308.58) |
| 2017 | $1,240 | 44 | Medtronic USA, Inc. ($329.76) |
All Payment Transactions
226 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $18.45 | General |
| Category: Opioid Analgesic | ||||||
| 10/29/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: Musculoskeletal | ||||||
| 10/02/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $24.96 | General |
| Category: Opioid Analgesic | ||||||
| 09/20/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $21.19 | General |
| Category: Opioid Analgesic | ||||||
| 08/20/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $9.87 | General |
| Category: Opioid Analgesic | ||||||
| 08/17/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: PAIN | ||||||
| 08/08/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $44.96 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 08/07/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.11 | General |
| Category: Opioid Analgesic | ||||||
| 07/29/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Neuromodulation | ||||||
| 07/23/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.94 | General |
| Category: Opioid Analgesic | ||||||
| 07/10/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $8.94 | General |
| Category: Opioid Analgesic | ||||||
| 06/28/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $27.38 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 06/21/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: PAIN | ||||||
| 06/18/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.20 | General |
| Category: Opioid Analgesic | ||||||
| 06/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.25 | General |
| Category: NEUROLOGY | ||||||
| 06/10/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $9.69 | General |
| Category: Opioid Analgesic | ||||||
| 05/22/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: NEUROSCIENCE | ||||||
| 05/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: NEUROSCIENCE | ||||||
| 05/15/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Gastroenterology | ||||||
| 05/14/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.93 | General |
| Category: Opioid Analgesic | ||||||
| 04/30/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $19.27 | General |
| Category: Opioid Analgesic | ||||||
| 04/24/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $13.92 | General |
| Category: Endocrinology | ||||||
| 04/20/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: PAIN | ||||||
| 04/16/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 778 | 1,607 | $274,713 | $129,933 |
| 2022 | 9 | 524 | 885 | $142,697 | $78,197 |
| 2021 | 8 | 1,301 | 3,137 | $589,451 | $220,421 |
| 2020 | 11 | 1,865 | 3,571 | $638,333 | $219,125 |
Total Patients
4,468
Total Services
9,200
Medicare Billing
$647,676
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 239 | 640 | $134,400 | $57,519 | 42.8% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 58 | 84 | $21,000 | $15,904 | 75.7% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 54 | 68 | $18,700 | $15,628 | 83.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 168 | 248 | $35,960 | $15,244 | 42.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 85 | 150 | $13,502 | $8,623 | 63.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $13,000 | $4,392 | 33.8% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 13 | 18 | $10,385 | $3,305 | 31.8% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 16 | 18 | $9,450 | $3,060 | 32.4% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 11 | 22 | $5,830 | $2,126 | 36.5% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 13 | 17 | $4,930 | $1,639 | 33.3% |
| 95924 | Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | Office | 2023 | 11 | 11 | $3,190 | $1,287 | 40.3% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2023 | 11 | 11 | $3,465 | $1,030 | 29.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 31 | 169 | $845.00 | $142.71 | 16.9% |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 2023 | 28 | 111 | $55.50 | $35.84 | 64.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 331 | $69,510 | $32,026 | 46.1% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 62 | 85 | $23,375 | $20,079 | 85.9% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 85 | 114 | $10,260 | $6,809 | 66.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 77 | 94 | $13,630 | $6,463 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 51 | 51 | $16,575 | $6,300 | 38.0% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 27 | 28 | $7,000 | $5,493 | 78.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 21 | 21 | $1,785 | $927.06 | 51.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 14 | 107 | $535.00 | $88.25 | 16.5% |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 2022 | 13 | 54 | $27.00 | $11.72 | 43.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 497 | 1,647 | $312,930 | $152,116 | 48.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 423 | 702 | $156,771 | $43,218 | 27.6% |
About Dr. Andreas Syllaba, DO
Dr. Andreas Syllaba, DO is a Neuromusculoskeletal Medicine & OMM healthcare provider based in Loveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063500932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andreas Syllaba, DO has received a total of $5,209 in payments from pharmaceutical and medical device companies, with $616.04 received in 2024. These payments were reported across 226 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($5,007).
As a Medicare-enrolled provider, Syllaba has provided services to 4,468 Medicare beneficiaries, totaling 9,200 services with total Medicare billing of $647,676. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Neuromusculoskeletal Medicine & OMM
- Location Loveland, OH
- Active Since 10/10/2006
- Last Updated 11/05/2020
- Taxonomy Code 204D00000X
- Entity Type Individual
- NPI Number 1063500932
Products in Payments
- XTAMPZA (Drug) $519.69
- Livalo (Drug) $308.58
- ADAPTIVESTIM (Device) $307.97
- NURTEC ODT (Drug) $291.17
- INTELLIS ADAPTIVESTIM (Device) $239.14
- Prialt (Drug) $232.41
- Senza Spinal Cord Stimulation System (Device) $224.08
- UBRELVY (Drug) $202.34
- RESTORE (Device) $139.71
- QULIPTA (Drug) $135.29
- Vascepa (Drug) $135.24
- Spectra WaveWriter (Device) $133.11
- Algovita (Device) $127.00
- WAVEWRITER ALPHA (Device) $125.15
- Qutenza (Drug) $124.01
- BOTOX (Biological) $117.79
- EUCRISA (Drug) $116.56
- RELISTOR (Drug) $113.00
- KYPHON Balloon Kyphoplasty (Device) $101.52
- Belbuca (Drug) $85.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.